SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-093570
Filing Date
2024-11-01
Accepted
2024-11-01 17:03:14
Documents
14
Period of Report
2024-10-30
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219564-8k_cerothera.htm   iXBRL 8-K 29382
  Complete submission text file 0001213900-24-093570.txt   249403

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cero-20241030.xsd EX-101.SCH 3798
3 XBRL DEFINITION FILE cero-20241030_def.xml EX-101.DEF 26673
4 XBRL LABEL FILE cero-20241030_lab.xml EX-101.LAB 36817
5 XBRL PRESENTATION FILE cero-20241030_pre.xml EX-101.PRE 25297
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0219564-8k_cerothera_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241419899
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)